Hypoparathyroidism-Focused Clinical Trial
Purpose
The purpose of this study is to find out how well canvuparatide works and how safe it is when given as an injection once a week to adults with HypoPT. Canvuparatide is designed to replace parathyroid hormone (PTH), which helps control calcium levels in the body. The goal of this study is to see if participants taking canvuparatide can stop using active vitamin D and reduce the amount of calcium supplements they need while still maintaining normal calcium levels in the blood. In this study, you will get either canvuparatide or placebo for the first 26 weeks of this study. A placebo looks like the study drug but does not contain any active ingredient. Researchers use a placebo to see if a study drug works better or is safer than the current standard of care for hypoparathyroidism.
Could this study be right for you?
Eligibility Criteria of Interest
- Documented diagnosis of post-surgical, chronic, genetic, idiopathic, or autoimmune hypoparathyroidism for atleast 12 months
- Taking calcium supplementation
- NO oral or intravenous bisphosphonates within 12 months
- No active cancer within the past 2 years (5 years for parathyroid carcinoma) or receiving current cancer treatment
- Cannot have previously participated in clinical study with canvuparatide (MBX 2109)
- Willing to participate in weekly injections